DanCann Pharma A/S: Carsten Trads, Chairman, comments on the Rights Issue

COPENHAGEN, Denmark, September 5, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma", “DCP” or the “Company”), a Danish company powered by cannabinoids, hereby comments on the Rights Issue communicated last week on behalf of the Chairman of the Company, Carsten Trads.

Carsten Trads, Chairman, comments:

Dear DanCann Pharma shareholders,

DanCann Pharma is on a growth journey towards the commercialization of the sale of medicinal cannabis from the company's production facility, Biotech Pharm1. It requires equity and liquidity. We have been lucky and skilled in getting capital from 4,500 shareholders since the company was founded in 2018. Now we are faced with raising new capital, and the Board of Directors of DanCann Pharma has decided to raise capital via a rights issue. We are very aware that the stock market is strongly challenged, but as we want to maintain the growth track and this method of raising capital, this was what the Board of Directors decided. This puts all shareholders on an equal standpoint, and everyone has the opportunity to enter the share. We are aware that a rights issue dilutes existing shareholders, but the Board of Directors has assessed that this solution was the most sustainable and creates room for long-term growth.

On behalf of the Board of Directors,

Carsten Trads, Chairman

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: [email protected]
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.